Which has preferable earnings & valuation, RVTY or TXG?

Revvity has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.86B 4.01 $241.20M $2.09 49.08 10x Genomics $642.82M 6.43 -$43.54M -$0.17 N/A

Is RVTY or TXG more profitable?

Revvity has a net margin of 8.26% compared to 10x Genomics' net margin of -3.55%. Revvity's return on equity of 8.00% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets Revvity 8.26% 8.00% 4.83% 10x Genomics -3.55% -2.86% -2.23%

Does the media refer more to RVTY or TXG?

In the previous week, Revvity had 7 more articles in the media than 10x Genomics. MarketBeat recorded 8 mentions for Revvity and 1 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.08 beat Revvity's score of 0.00 indicating that 10x Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 10x Genomics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, TXG or CAMT?

Camtek has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Camtek, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 10x Genomics $642.82M 6.43 -$43.54M -$0.17 N/A Camtek $496.07M 16.30 $50.72M $0.87 202.85

Is TXG or CAMT more profitable?

Camtek has a net margin of 9.63% compared to 10x Genomics' net margin of -3.55%. Camtek's return on equity of 22.26% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -3.55% -2.86% -2.23% Camtek 9.63% 22.26% 11.70%

Does the media favor TXG or CAMT?

In the previous week, Camtek had 4 more articles in the media than 10x Genomics. MarketBeat recorded 5 mentions for Camtek and 1 mentions for 10x Genomics. Camtek's average media sentiment score of 1.00 beat 10x Genomics' score of 0.08 indicating that Camtek is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Camtek 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BIO.B or TXG?

10x Genomics has a consensus target price of $23.17, suggesting a potential downside of 28.86%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Bio-Rad Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Rad Laboratories 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 10x Genomics 1 Sell rating(s) 10 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media refer more to BIO.B or TXG?

In the previous week, Bio-Rad Laboratories and Bio-Rad Laboratories both had 1 articles in the media. 10x Genomics' average media sentiment score of 0.08 beat Bio-Rad Laboratories' score of 0.00 indicating that 10x Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Rad Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 10x Genomics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TXG or ST?

In the previous week, Sensata Technologies had 13 more articles in the media than 10x Genomics. MarketBeat recorded 14 mentions for Sensata Technologies and 1 mentions for 10x Genomics. Sensata Technologies' average media sentiment score of 0.79 beat 10x Genomics' score of 0.08 indicating that Sensata Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensata Technologies 5 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

10x Genomics (TXG) Competitors

$32.56 +0.41 (+1.26%)

As of 09:32 AM Eastern

Compare

TXG vs. PACB, RVTY, CAMT, BIO.B, and ST

Should you buy 10x Genomics stock or one of its competitors? MarketBeat compares 10x Genomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 10x Genomics include Pacific Biosciences of California (PACB), Revvity (RVTY), Camtek (CAMT), Bio-Rad Laboratories (BIO.B), and Sensata Technologies (ST).

How does 10x Genomics compare to Pacific Biosciences of California?

Pacific Biosciences of California (NASDAQ:PACB) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	3.10	-$546.38M	-$0.43	N/A
10x Genomics	$642.82M	6.43	-$43.54M	-$0.17	N/A

Pacific Biosciences of California has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market.

10x Genomics has a net margin of -3.55% compared to Pacific Biosciences of California's net margin of -80.35%. 10x Genomics' return on equity of -2.86% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%
10x Genomics	-3.55%	-2.86%	-2.23%

Pacific Biosciences of California currently has a consensus price target of $1.83, indicating a potential upside of 14.94%. 10x Genomics has a consensus price target of $23.17, indicating a potential downside of 28.86%. Given Pacific Biosciences of California's higher possible upside, equities research analysts plainly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, 10x Genomics had 1 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 1 mentions for 10x Genomics and 0 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 1.22 beat 10x Genomics' score of 0.08 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Overall Sentiment
Pacific Biosciences of California	Positive
10x Genomics	Neutral

84.7% of 10x Genomics shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by insiders. Comparatively, 8.8% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

10x Genomics beats Pacific Biosciences of California on 12 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Revvity?

Revvity (NYSE:RVTY) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Revvity currently has a consensus target price of $107.73, suggesting a potential upside of 5.02%. 10x Genomics has a consensus target price of $23.17, suggesting a potential downside of 28.86%. Given Revvity's stronger consensus rating and higher possible upside, research analysts plainly believe Revvity is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Revvity has a net margin of 8.26% compared to 10x Genomics' net margin of -3.55%. Revvity's return on equity of 8.00% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.26%	8.00%	4.83%
10x Genomics	-3.55%	-2.86%	-2.23%

86.7% of Revvity shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Comparatively, 8.8% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Revvity had 7 more articles in the media than 10x Genomics. MarketBeat recorded 8 mentions for Revvity and 1 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.08 beat Revvity's score of 0.00 indicating that 10x Genomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
10x Genomics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revvity has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market.

Revvity has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	4.01	$241.20M	$2.09	49.08
10x Genomics	$642.82M	6.43	-$43.54M	-$0.17	N/A

Summary

Revvity beats 10x Genomics on 11 of the 15 factors compared between the two stocks.

How does 10x Genomics compare to Camtek?

10x Genomics (NASDAQ:TXG) and Camtek (NASDAQ:CAMT) are both mid-cap measuring and control equipment companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

In the previous week, Camtek had 4 more articles in the media than 10x Genomics. MarketBeat recorded 5 mentions for Camtek and 1 mentions for 10x Genomics. Camtek's average media sentiment score of 1.00 beat 10x Genomics' score of 0.08 indicating that Camtek is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Camtek	1 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10x Genomics currently has a consensus price target of $23.17, suggesting a potential downside of 28.86%. Camtek has a consensus price target of $174.33, suggesting a potential downside of 1.22%. Given Camtek's stronger consensus rating and higher probable upside, analysts plainly believe Camtek is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Camtek	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 41.9% of Camtek shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Comparatively, 79.4% of Camtek shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

10x Genomics has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market. Comparatively, Camtek has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

Camtek has a net margin of 9.63% compared to 10x Genomics' net margin of -3.55%. Camtek's return on equity of 22.26% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Camtek	9.63%	22.26%	11.70%

Camtek has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Camtek, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	6.43	-$43.54M	-$0.17	N/A
Camtek	$496.07M	16.30	$50.72M	$0.87	202.85

Summary

Camtek beats 10x Genomics on 13 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO.B) and 10x Genomics (NASDAQ:TXG) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

10x Genomics has a consensus target price of $23.17, suggesting a potential downside of 28.86%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Bio-Rad Laboratories has a net margin of 6.52% compared to 10x Genomics' net margin of -3.55%. Bio-Rad Laboratories' return on equity of 3.56% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	6.52%	3.56%	2.49%
10x Genomics	-3.55%	-2.86%	-2.23%

Bio-Rad Laboratories has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market.

In the previous week, Bio-Rad Laboratories and Bio-Rad Laboratories both had 1 articles in the media. 10x Genomics' average media sentiment score of 0.08 beat Bio-Rad Laboratories' score of 0.00 indicating that 10x Genomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
10x Genomics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bio-Rad Laboratories has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.15	$759.90M	$6.07	50.11
10x Genomics	$642.82M	6.43	-$43.54M	-$0.17	N/A

Summary

Bio-Rad Laboratories beats 10x Genomics on 8 of the 15 factors compared between the two stocks.

How does 10x Genomics compare to Sensata Technologies?

10x Genomics (NASDAQ:TXG) and Sensata Technologies (NYSE:ST) are both mid-cap measuring and control equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 99.4% of Sensata Technologies shares are held by institutional investors. 8.8% of 10x Genomics shares are held by insiders. Comparatively, 0.7% of Sensata Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

10x Genomics has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market. Comparatively, Sensata Technologies has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

In the previous week, Sensata Technologies had 13 more articles in the media than 10x Genomics. MarketBeat recorded 14 mentions for Sensata Technologies and 1 mentions for 10x Genomics. Sensata Technologies' average media sentiment score of 0.79 beat 10x Genomics' score of 0.08 indicating that Sensata Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensata Technologies	5 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

10x Genomics presently has a consensus price target of $23.17, suggesting a potential downside of 28.86%. Sensata Technologies has a consensus price target of $47.70, suggesting a potential downside of 9.06%. Given Sensata Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Sensata Technologies is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Sensata Technologies	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Sensata Technologies has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Sensata Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	6.43	-$43.54M	-$0.17	N/A
Sensata Technologies	$3.70B	2.06	$31.30M	$0.31	169.19

Sensata Technologies has a net margin of 1.28% compared to 10x Genomics' net margin of -3.55%. Sensata Technologies' return on equity of 18.23% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Sensata Technologies	1.28%	18.23%	7.34%

Summary

Sensata Technologies beats 10x Genomics on 12 of the 15 factors compared between the two stocks.

Get 10x Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXG vs. The Competition

Export

Metric	10x Genomics	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.14B	$1.57B	$6.47B	$12.54B
Dividend Yield	N/A	N/A	2.69%	5.22%
P/E Ratio	-191.61	77.62	22.12	24.18
Price / Sales	6.43	6.92	524.88	112.26
Price / Cash	N/A	22.87	41.34	57.13
Price / Book	5.22	4.77	9.95	6.72
Net Income	-$43.54M	-$54.76M	$3.57B	$337.19M
7 Day Performance	16.35%	-3.52%	-2.46%	-0.75%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	248.66%	-2.71%	26.57%	33.09%

10x Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXG 10x Genomics	1.1983 of 5 stars	$32.57 +1.3%	$23.17 -28.9%	+253.0%	$4.14B	$642.82M	N/A	1,240
PACB Pacific Biosciences of California	1.5878 of 5 stars	$1.22 flat	$1.83 +50.3%	+50.5%	$378.93M	$160.01M	N/A	730	Positive News
RVTY Revvity	1.9655 of 5 stars	$96.93 0.0%	$107.73 +11.1%	+11.2%	$10.82B	$2.86B	46.38	11,000	Analyst Forecast Analyst Revision
CAMT Camtek	2.6445 of 5 stars	$167.37 flat	$174.33 +4.2%	+169.6%	$7.67B	$496.07M	192.38	400	Positive News Gap Down
BIO.B Bio-Rad Laboratories	N/A	$267.43 flat	N/A	+21.6%	$7.16B	$2.58B	44.06	8,200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXG) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

10x Genomics (TXG) Competitors

TXG vs. PACB, RVTY, CAMT, BIO.B, and ST

How does 10x Genomics compare to Pacific Biosciences of California?

Summary

How does 10x Genomics compare to Revvity?

Summary

How does 10x Genomics compare to Camtek?

Summary

How does 10x Genomics compare to Bio-Rad Laboratories?

Summary

How does 10x Genomics compare to Sensata Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG vs. The Competition

10x Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

10x Genomics (TXG) Competitors

TXG vs. PACB, RVTY, CAMT, BIO.B, and ST

How does 10x Genomics compare to Pacific Biosciences of California?

Which has higher earnings & valuation, PACB or TXG?

Which has more risk & volatility, PACB or TXG?

Is PACB or TXG more profitable?

Do analysts prefer PACB or TXG?

Does the media refer more to PACB or TXG?

Do institutionals and insiders believe in PACB or TXG?

Summary

How does 10x Genomics compare to Revvity?

Do analysts rate RVTY or TXG?

Is RVTY or TXG more profitable?

Do insiders & institutionals hold more shares of RVTY or TXG?

Does the media refer more to RVTY or TXG?

Which has more risk and volatility, RVTY or TXG?

Which has preferable earnings & valuation, RVTY or TXG?

Summary

How does 10x Genomics compare to Camtek?

Does the media favor TXG or CAMT?

Do analysts rate TXG or CAMT?

Do insiders and institutionals have more ownership in TXG or CAMT?

Which has more risk & volatility, TXG or CAMT?

Is TXG or CAMT more profitable?

Which has preferable valuation & earnings, TXG or CAMT?

Summary

How does 10x Genomics compare to Bio-Rad Laboratories?

Do institutionals and insiders have more ownership in BIO.B or TXG?

Do analysts rate BIO.B or TXG?

Is BIO.B or TXG more profitable?

Which has more risk and volatility, BIO.B or TXG?

Does the media refer more to BIO.B or TXG?

Which has better valuation and earnings, BIO.B or TXG?

Summary

How does 10x Genomics compare to Sensata Technologies?

Do institutionals & insiders have more ownership in TXG or ST?

Which has more risk and volatility, TXG or ST?

Does the media favor TXG or ST?

Do analysts prefer TXG or ST?

Which has better earnings and valuation, TXG or ST?

Is TXG or ST more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG vs. The Competition

10x Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools